一分钟看懂
这是一项关于淋巴瘤的II 期研究，登记的药物或干预包括Zanubrutinib；Rituximab，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Zanubrutinib；Rituximab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University · 广州
公开的入选条件
- Key inclusion Criteria:
- 1. Mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma confirmed by histopathology.
- 2. Newly diagnosed with Ann Arbor stage III-IV or relapsed MALT after local treatment .
- 3. No prior systemic anti-lymphoma therapy (except for H. pylori eradication therapy in H. pylori-positive gastric MALT patients).
- 4. No histopathological transformation to high-grade lymphoma.
- 5. At least one measurable lesion according to the Lugano 2014 criteria.
- 7\. Age ≥ 18 years, with no gender restrictions. 7. An ECOG performance status score of 0-2. 8. An expected survival time of more than 12 months. 9. Adequate bone marrow, cardiac, pulmonary, liver, and kidney function. 10. Willing to participate in the clinica
- Key exclusion Criteria:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06647732；登记信息更新于 2026-09-15。